Tech Company Financing Transactions
Kronos Bio Funding Round
On 8/26/2020, Kronos Bio raised $155 million in investment from BlackRock, Perceptive Advisors and Casdin Capital.
Transaction Overview
Company Name
Announced On
8/26/2020
Transaction Type
Debt
Amount
$155,000,000
Round
Undisclosed
Investors
Proceeds Purpose
This capital will help propel Kronos through our upcoming period of clinical development.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
1300 So. El Camino Real 300
San Mateo, CA 94402
USA
San Mateo, CA 94402
USA
Phone
Undisclosed
Website
Email Address
Overview
Kronos Bio (Nasdaq: KRON) is dedicated to the research and development of first-in-class therapies that modulate historically recalcitrant cancer targets.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Norbert Bischofberger
Chief Financial Officer
Yasir Al-Wakeel
Chief Marketing Officer
Jorge DiMartino
Chief Operating Officer
Barbara Kosacz
Chief Scientific Officer
Christopher Dinsmore
Vice President
Christopher Lee
Vice President
Charles Lin
Vice President
Douglas Saffran
Vice President
Wes Trotter
VP - Bus. Development
Philip Gutry
VP - Operations
Zung To
VP - Regulatory Affairs
Jennifer Nicholson
Browse more venture capital transactions:
Prev: 8/26/2020: Kinnate Biopharma venture capital transaction
Next: 8/26/2020: Turing venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from company press releases and news coverage. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs